Authors


Glenn Beard, MD

Latest:

Insight into a Forgotten Disease: Lemierre's Syndrome

Lemierre's syndrome is characterized by oropharyngeal infection, usually by Fusobacterium necrophorum, followed by septic thrombophlebitis of the internal jugular vein with embolization to the lungs and other organs. Since the introduction of antibiotics, Lemierre's syndrome has become relatively rare and is usually unsuspected until blood culture results are available. In the preantibiotic era, ligation of the internal jugular vein on the affected side to prevent septicemia was the only recognized treatment. Current therapy is a 4- to 6-week course of antibiotics, such as penicillin G, clindamycin, or metronidazole, directed against F necrophorum. The use of anticoagulation is still controversial.






David Brieger, MBBS, PhD: From the Department of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Latest:

Combining warfarin and antiplatelet therapy after coronary stenting

We conducted an observational study to compare singleantiplatelet therapy with dualantiplatelet therapy among patients requiring long-term warfarin therapy after coronary stenting. Results showed that there was no difference in mortality or myocardial infarction between the 2 treatment regimens at 6 months, with no excess in-hospital bleeding; however, larger trials are needed to determine firm recommendations.


Joanne LaFleur, PharmD, MSPH

Latest:

Bisphosphonates' Growing Role in Breast Cancer

Intravenous bisphosphonates, often used to treat metastases and bone pain in breast cancer patients, are now being used by clinicians for osteoporosis in these patients—pharmacists need to recommend appropriate screening and treatment.



Stanley Katz, MD is chief of cardiology, North Shore University Hospital, Manhassett, New York.

Latest:

Different means to the same end, or just different?

The study by Schuijf and Bax, which compares multislice computed tomography (CT) versus myocardial perfusion imaging, is very timely, as this new cardiac imaging modality has gained rapid acceptance by cardiologists for managing patients.



Joseph B. Muhlestein, MD1,2: From the 1Cardiovascular Department, LDS Hospital

Latest:

Reduction of inflammatory biomarkers through the use of hyperlipidemia drugs in patients with diabetes

Diabetes and inflammation influence the development of atherosclerosis. We performed a study that showed the inflammatory markers high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 were lowered with the use of fenofibrate, simvastatin, and combination therapy. The anti-inflammatory effects were most pronounced among patients with elevated baseline inflammatory markers. Combination therapy significantly altered lipid concentrations and exerted a greater positive effect on low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides than monotherapy with either drug.


Joseph Dell'Orfano, MD

Latest:

Cardiac resynchronization in a patient with Class IV heart failure and narrow QRS-the role of mechanical dyssynchrony

Cardiac resynchronization treatment (CRT) has moved into the mainstream of patient care after several randomized studies have demonstrated improved quality of life, reversed remodeling, and decreased heart failure hospitalizations. More recently, 2 large studies have demonstrated a mortality benefit of CRT independent of implantable cardioverter defibrillator


Alan G.Wasserman, MD is Eugene Meyer Professor of Medicine

Latest:

Did you see it move?

The lack of a reliable quantitative measurement analysis package for regional left ventricular wall motion is not new.




Tasneem Z. Naqvi, MD, MRCP, is associate director, Cardiac Non-invasive Lab at Cedar's Sinai Medical Center

Latest:

Prevalent atherosclerosis-Choose your biomarker

Circulating biomarkers have been used in cardiovascular medicine as predictors of incident or prevalent disease.


Steven Wright, MD

Latest:

REMS Doesn't Have to Be a ‘Four-letter Word'

Risk management with patients on opioid therapy offers the opportunity to improve communication and strengthen the physician-patient relationship.




Rare Disease Editorial Staff

Latest:

Venetoclax Approved for Older Patients With AML

The drug is approved as a treatment for adult patients with newly-diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.




Daniel I. Kim, MD, FACP

Latest:

Leprosy: Forgotten in America?

Leprosy was well recognized in antiquity and was often associated with social stigma. In 1873, Dr G. Hansen first identified Mycobacterium leprae as the cause for this condition, which was then named Hansen's disease. Not until the 20th century was specific treatment developed. Leprosy remains endemic to certain areas in the world, especially tropical and subtropical zones. Overall prevalence has decreased, but the reported incidence of leprosy has remained steady, even in the United States. In light of the significant morbidity associated with the disease, physicians must remain vigilant for its signs and symptoms even in developed countries, especially with increasing travel to and from endemic areas.


Anaya Mitchell

Latest:

Mestinon and Other Ways to Treat Myasthenia Gravis

In this video, Beth Stein, M.D., and myasthenia gravis patient Anaya Mitchell discuss mestinon, steroids, and other treatment methods for myasthenia gravis.



Steven Daviss, MD

Latest:

Doctors to Go to Jail for Asking Patients about Guns in the Home

If psychiatrists are involved in restoration of gun rights, why could they be banned from asking questions about ownership?





Ingo Paetsch, MD: From the Department of Internal Medicine/Cardiology, German Heart Institute, Berlin, Germany.

Latest:

Cardiac magnetic resonance stress tests in coronary heart disease

We evaluated the prognostic value of cardiac magnetic resonance (CMR) stress testing with direct comparison of adenosine stress first-pass perfusion and dobutamine stress wall motion imaging among 513 subjects with known or suspected coronary heart disease over a median follow-up period of 2.3 years. Positive results on CMR stress testing identified subjects at high risk for subsequent cardiac events (nonfatal myocardial infarction or cardiac death), whereas normal CMR stress test results were associated with a very low annual cardiac event rate.

© 2024 MJH Life Sciences

All rights reserved.